Drug profile · INN
gonadorelin hydrochloride
FACTREL
gonadorelin hydrochloride (FACTREL) is a gonadotropin-releasing hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — gonadorelin hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 5
- Programs
- 2
- Data quality
- 0.84
Quick answer
gonadorelin hydrochloride (FACTREL) is a gonadotropin-releasing hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Gonadotropin-releasing hormone receptor agonist
Primary target: Gonadotropin-releasing hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12351581
Compounds for FGFR inhibition
granted -
US 11718576
Compositions and methods comprising resveratrol
granted -
US 11339112
Compositions and methods comprising resveratrol
granted -
US 10836702
Compositions and methods comprising resveratrol
granted -
US 10301248
Compositions and methods comprising resveratrol
granted
Frequently asked questions
What is gonadorelin hydrochloride?
gonadorelin hydrochloride (FACTREL) is a gonadotropin-releasing hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for gonadorelin hydrochloride?
FACTREL is a marketed brand name for gonadorelin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of gonadorelin hydrochloride?
gonadorelin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.